宁夏医科大学附属医院32年间胃镜室食道癌检出情况回顾性分析
|
摘要
目的对宁夏医科大学附属医院自1975年11月11日,至2006年12月31日32年间胃镜室食道癌检出率以及检出的食道癌病人一般情况、病变部位、病理类型、总体病理类型变化趋势进行临床流行病学研究。
方法查阅宁夏医科大学附属医院胃镜室1975年11月11日～2006年12月31日32年间胃镜检查记录,统计检查人次数,记录胃镜下诊断为食道癌病人的姓名、性别、年龄、民族、病变部位,翻阅病理科病理检查记录,核对姓名、性别、年龄,详细记录病理诊断为食道癌病人的一般情况及病理类型,按诊断时间分为四组,进行统计学分析。
结果32年间我院胃镜室共进行96727人次胃镜检查,检出食道癌1616人,食道癌检出率1.67%,按10年统计32年间食道癌检出率无变化趋势,食道癌男女比例为2.58∶1,以40～65岁之间的病人为多(占59.65%);病变部位以食道中段为主(占70.7%),下段次之,上段最少;病理类型仍以鳞癌为主,占88.2%,腺癌占11.8%;汉族、回族、蒙古族之间食道鳞癌和腺癌发病没有差异;32年来食道下段腺癌的构成比渐增高。
结论宁夏医科大学附属医院胃镜室32年间食道癌检出率无明显变化趋势,提示宁夏周边地区该病发病率无变化;食道癌以40～65岁年龄段好发,65岁以上人群食道癌发病率有增加趋势;不同年龄段腺癌发病没有差异;宁夏周边地区汉族、回族、蒙古族食道鳞癌、腺癌发病没有差异;食道下段腺癌发病有增加趋势。
目的研究Lugol’s液进行食道染色联合MUC2检测对Barrett食道的诊断价值。
方法检查前确认患者无碘过敏史,对胃镜下初步诊断为Barrett食道的患者,随机分为两组,A组为对照组,在紧靠齿状线下方、齿状线舌形突出、齿状线上岛形橘红色粘膜处取活检2～4块,送常规病理检查;B组为实验组,对胃镜下初步诊断的病例,行2% Lugol’s液10～20ml食道染色,1～3分钟食道粘膜迅速染色,在食道不着色区取活检(靶向活检)2～4块送常规病理检查,同时行免疫组化检测MUC2表达情况。
结果A组常规病理确诊为Barrett食道12例,其中3例为肠化型Barrett食道;B组病理诊断为Barrett食道21例,常规病理诊断7例为肠化型,病理诊断的BE中有13例MUC2阳性表达,两组BE检出率之间比较,χ~2=4.4,P=0.036<0.05,差异有显著性;两组肠化型BE检出率之间比较,χ~2=7.232,P=0.007<0.05,差异有显著性。
结论Lugol’s液食道染色进行靶向活检可以提高Barrett食道的诊断率,MUC2检测显著提高了肠化型BE的诊断率。
Objective To analyze the clinical charater and pathological type of the patients with esophageal cancer.from 1975 to 2006, in The Affiliated Hospital of Ningxia Medical University.
Methods All the cases were divided into 4 groups according to the different time orders from 1975-2006, in the endoscopy unit of the Affiliated Hospital of NingXia Medical University. The gender, age, nationality, lesion, pathological type of patients were collected and statistically analyzed.
Result The 96727 cases were examined by endoscopy and 1616 esophageal cancer were found.The incidence rate of esophageal cancer was 1.76%. Male vs famale was 2.58.The more cases were between 40 and 65 years old. And the more lesion area located in the middle esophagus. The squamous cell carcinoma was 88.2% in all the type of esophageal carcinoma. Most of the esophageal adenocarcinoma were found in the distal esophagus and the incidence rate is 11.8%. And it was found the distal esophageal adenocarcinoma increased through the years.
Coclusion There were no significant difference (P>0.05) in the detective rate of esophageal cancer between the 4 groups.And there were also no significant difference (P>0.05) between the ages and nationality in incidence of adenocacinoma. There was an increased incidence of esophageal cancer with increasing age.It was found the distal esophageal adenocarcinoma increased through the years.
Objective To study the expression of MUC2 combines of Lugol’s solution staining in the patients with Barrett’s esophagus.
Methods All the 44 Barrett’s esophagus were diagnosed by the endoscopy.They were randomized into two groups. Group A(control group) were 20 cases, 2～4 biopsies were taken from orange areas of esophagus. Group B(experiment group)were 24 cases stained with 10～20ml Lugol’s solution first.After 1～3min, 2～4 biopsies were taken from unstained areas . The expression of the MUC2 were detected by immunohistochemistry in the group B.
Results 12 cases in the group A were confirmed Barrett’s esophagus by pathologist, and 3 cases were found the intestinal metaplasis in the Barrett’s esophagus. 21 cases in the B group were were confirmed Barrett’s esophagus by pathologist, and 7 cases were found the intestinal metaplasis in the Barrett’s esophagus.And the MUC2 were positive in 13 cases. The detectiive rate of Barrett’s esophagus was significant difference between group A and group B (χ~2=4.4, P=0.0362<0.05). And the detection of the intestinal metaplasia was also was significant difference between group A and group B (χ~2=7.232, P=0.007<0.01).
Conclusion The Lugol’s solution staining could increase the diagnostic rate of Barrett’s esophagus, and combination of detecting the expression of MUC2 can increase the diagnostic rate of the intestinal metaplasia.
方法查阅宁夏医科大学附属医院胃镜室1975年11月11日～2006年12月31日32年间胃镜检查记录,统计检查人次数,记录胃镜下诊断为食道癌病人的姓名、性别、年龄、民族、病变部位,翻阅病理科病理检查记录,核对姓名、性别、年龄,详细记录病理诊断为食道癌病人的一般情况及病理类型,按诊断时间分为四组,进行统计学分析。
结果32年间我院胃镜室共进行96727人次胃镜检查,检出食道癌1616人,食道癌检出率1.67%,按10年统计32年间食道癌检出率无变化趋势,食道癌男女比例为2.58∶1,以40～65岁之间的病人为多(占59.65%);病变部位以食道中段为主(占70.7%),下段次之,上段最少;病理类型仍以鳞癌为主,占88.2%,腺癌占11.8%;汉族、回族、蒙古族之间食道鳞癌和腺癌发病没有差异;32年来食道下段腺癌的构成比渐增高。
结论宁夏医科大学附属医院胃镜室32年间食道癌检出率无明显变化趋势,提示宁夏周边地区该病发病率无变化;食道癌以40～65岁年龄段好发,65岁以上人群食道癌发病率有增加趋势;不同年龄段腺癌发病没有差异;宁夏周边地区汉族、回族、蒙古族食道鳞癌、腺癌发病没有差异;食道下段腺癌发病有增加趋势。
目的研究Lugol’s液进行食道染色联合MUC2检测对Barrett食道的诊断价值。
方法检查前确认患者无碘过敏史,对胃镜下初步诊断为Barrett食道的患者,随机分为两组,A组为对照组,在紧靠齿状线下方、齿状线舌形突出、齿状线上岛形橘红色粘膜处取活检2～4块,送常规病理检查;B组为实验组,对胃镜下初步诊断的病例,行2% Lugol’s液10～20ml食道染色,1～3分钟食道粘膜迅速染色,在食道不着色区取活检(靶向活检)2～4块送常规病理检查,同时行免疫组化检测MUC2表达情况。
结果A组常规病理确诊为Barrett食道12例,其中3例为肠化型Barrett食道;B组病理诊断为Barrett食道21例,常规病理诊断7例为肠化型,病理诊断的BE中有13例MUC2阳性表达,两组BE检出率之间比较,χ~2=4.4,P=0.036<0.05,差异有显著性;两组肠化型BE检出率之间比较,χ~2=7.232,P=0.007<0.05,差异有显著性。
结论Lugol’s液食道染色进行靶向活检可以提高Barrett食道的诊断率,MUC2检测显著提高了肠化型BE的诊断率。
Objective To analyze the clinical charater and pathological type of the patients with esophageal cancer.from 1975 to 2006, in The Affiliated Hospital of Ningxia Medical University.
Methods All the cases were divided into 4 groups according to the different time orders from 1975-2006, in the endoscopy unit of the Affiliated Hospital of NingXia Medical University. The gender, age, nationality, lesion, pathological type of patients were collected and statistically analyzed.
Result The 96727 cases were examined by endoscopy and 1616 esophageal cancer were found.The incidence rate of esophageal cancer was 1.76%. Male vs famale was 2.58.The more cases were between 40 and 65 years old. And the more lesion area located in the middle esophagus. The squamous cell carcinoma was 88.2% in all the type of esophageal carcinoma. Most of the esophageal adenocarcinoma were found in the distal esophagus and the incidence rate is 11.8%. And it was found the distal esophageal adenocarcinoma increased through the years.
Coclusion There were no significant difference (P>0.05) in the detective rate of esophageal cancer between the 4 groups.And there were also no significant difference (P>0.05) between the ages and nationality in incidence of adenocacinoma. There was an increased incidence of esophageal cancer with increasing age.It was found the distal esophageal adenocarcinoma increased through the years.
Objective To study the expression of MUC2 combines of Lugol’s solution staining in the patients with Barrett’s esophagus.
Methods All the 44 Barrett’s esophagus were diagnosed by the endoscopy.They were randomized into two groups. Group A(control group) were 20 cases, 2～4 biopsies were taken from orange areas of esophagus. Group B(experiment group)were 24 cases stained with 10～20ml Lugol’s solution first.After 1～3min, 2～4 biopsies were taken from unstained areas . The expression of the MUC2 were detected by immunohistochemistry in the group B.
Results 12 cases in the group A were confirmed Barrett’s esophagus by pathologist, and 3 cases were found the intestinal metaplasis in the Barrett’s esophagus. 21 cases in the B group were were confirmed Barrett’s esophagus by pathologist, and 7 cases were found the intestinal metaplasis in the Barrett’s esophagus.And the MUC2 were positive in 13 cases. The detectiive rate of Barrett’s esophagus was significant difference between group A and group B (χ~2=4.4, P=0.0362<0.05). And the detection of the intestinal metaplasia was also was significant difference between group A and group B (χ~2=7.232, P=0.007<0.01).
Conclusion The Lugol’s solution staining could increase the diagnostic rate of Barrett’s esophagus, and combination of detecting the expression of MUC2 can increase the diagnostic rate of the intestinal metaplasia.
引文
[1] Boyce HW, Esophageal malignancies and premalignant conditions, In: Kirsner J, ed. The Growth of Gastroenterologic Knowledge During the Twentieth Century. Malvem, Pa; Lea Fehiger, 1994: 11-34.
[2]孙燕,哈献文.临床肿瘤诊疗关键[M]南宁;广西科学技术出版社, 1999;09:313.
[3] KE L. Mortality and incidence trends from esophagus cancer in selected geographic areas of China cirea 1970-90 [J]. Int J Cancer 2002, 102(3): 271-274.
[4] Zhiwei Dong, Pingzhang Tang, Liandi Li, et al. The Strategy for EsophagealCancer Control in High-risk Areas of China. Jpn. J. Clin. Oncol., Feb 2002; 32: S10-S12.
[5]李超民,刘佳萍,何洪,等.邵阳市食管癌207例临床及内镜分析[J].中国内镜杂志, 2004, 10(3): 70-71.
[6]李宁燕,何慧萍,汪雪琦,等. 367例食管癌胃镜诊断及病理分析[J].实用诊断与治疗杂志, 2004, 18(6): 554-554.
[7] G Launoy, J Faivre, P Pienkowski, et al. Changing Pattern of Oesophageal Cancer Incidence in France. Int. J.Epidemiol., Apr1994, 23: 246-251.
[8] Akiko Shibata, Toru Matsuda, Wakiko Ajiki, et al. Trend in Incidence of A denocarcinoma of the Esophagus in Japan, 1993–2001. Japanese Journalof Clinical Oncology, 2008, 38(7): 464-468.
[9]汤钊猷.现代肿瘤学[M].上海医科大学,1993;06:456-484.
[10]侯浚,陈志峰,贺宇彤.食道癌的流行病学.河北职工医学院学报[J]. 2000, 127(4):28-30.
[11]郭国平,华召来,周琴等.扬州市食道癌流行及治疗情况分析[J].中国肿瘤, 2001, 10(2):105-107.
[12]罗好曾,周俊年,刘文林.武威市食道癌发病对比分析.肿瘤防治学杂志[J].2002, 9(2):121-123.
[13]朱健,姚红玉,张永辉.启东市1972～2000年食道癌发病趋势分析.交通医学[J]. 2002, 16(4):426-427.
[14] Gary D. Stoner, Ashok Gupta. Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis, 2001, 22 (11): 1737-1746.
[15]魏矿荣,沈逸雄,梁治恒,等.广东省中山市1970～1999年食道癌发病动态分析.实用肿瘤学杂志[J]. 2003, 17(4):246-249.
[16]余红平,施侣元,幺鸿雁.吸烟、饮酒与食管癌关系的Meta-分析.中国慢性病预防与控制[J]. 2003, 11(1): 1-2.
[17]肖郑生,张立新,杨海军,等.食管癌3954例切除标本临床病理分析.中国肿瘤临床与康复[J]. 2002, 9(1): 59-61.
[18]章宏,厉有名,王伟.食道腺癌临床流行病学研究.中华消化杂志, 2003, 23:696-697.
[19] Douglas A Corley, Patricia A Buffler. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. International Journal of Epidemiology, 2001, 30: 1415-1425.
[20] Ritenbaugh C, Sampliner R, Aickin M, et al. Risk factor for Barrett’s oesophagus: a life history approach to bahavioural assessment in the distant past. Eur J Cancer Prev, 1995, 4(6): 459-468.
[21]林三仁,许国铭,胡品津等.中国胃食管反流病共识意见.胃肠病学, 2007, 12(4):233-239.
[22] Devesa SS, Blot WJ, Fraumeni JF, et al. Changing patterns in the irrcidence of esophageal and gastric carcinoma in the United States. Cancer, 1998, 83(10): 2049-2053.
[23] Xiaoxin Chen , Chung S. Yang. Esophageal adenocarcinoma: a review and perspectiveson the mechanism of carcinogenesis and chemoprevention.Carcinogenesis, 22(8): 1119 -1129.
[24] Ofman JJ. The relation between gastroesophageal reflux disease and esophageal and head and neck cancer; a critical appraisal of epidemiologic literature. Am J Med, 2001, 111(Suppl 8A): 124S-129S.
[25]刘巍,郝希山,晋颖,等. 4329例手术后食管癌临床病理资料分析.中国肿瘤临床[J]. 2008, 35(5): 241-244.
[26]马兴刚,黄根牙,张菊,等.淮安市666例食管癌的临床、内镜及病理分析.医学综述, 2008, 14(17):2705.
[27]厉有名.重视食管腺癌的基础和临床研究.中华消化杂志, 2002, 22:261-262.
[28] Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalenceand clinical data. Gastroenterology, 1999, 116: 277-285.
[29]汤绍辉,杨冬华. Barrett食管.杨冬华.消化系统疾病治疗学[M].第1版.北京:人民卫生出版社, 2005, 60.
[30] Kulke MH, Odze RD, Thakore KS, et al. Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett’s oesophagus associated adenocar cinima[J]. Br J Cancer, 2001, 84(6): 748-753.
[31] Menges M, Muller M, Zeitzm, Increased acide and bilentefux in Barrett’s esophagus compared to reflux esophagitis,and effect of proton pump inhibitor therapy [J]. Am J Gastroenterol, 2001, 96(3): 331-337.
[32]侯晓华.胃食管反流病.王吉耀.内科学[M].第一版.北京:人民卫士出版社, 2005, 401.
[33] Yehe, Hsu CT, Ho AS, et al. Esophagitis and Barrett’s esophagus in Tai Wan: a high frequency than expected [J]. Dis Sci, 1997, 42: 702-706.
[34]赵京晶,房殿春. Barrett食管放大内镜下分型与组织病理学关系的研究.中华消化内镜杂志[J]. 2005, 22(3):154-156.
[35]赵立群,徐峰,杨观瑞,等. Barrett食管在国人中发病率及P53、EGF1在其中的表达河南肿瘤学杂志[J]. 1997,(10)3:161-164.
[1] Burjonrappa SC, Reddimasu S, Nawaz Z, et al. Mucin expression profile in Barrett’s, dysplasia, adenocarioma sequence in the esophagus. Indian J Cancer, 2007, 44: 1.
[2]林三仁,许国铭,胡品津等.中国胃食管反流病共识意见.胃肠病学, 2007, 12(4):233-239.
[3]薛寒冰译. Barrett食管诊断和治疗-美国胃肠病学会芝加哥会议总结.胃肠病学, 2005, 10(3):182.
[4]小森真人. Barrett上皮的发生机制.日本医学介绍, 2002, 23(1):5.
[5] Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett’s esophagus. in Oimsted Country, Minnesota. Gut, 2001, 48(3):304-309
[6] Andreollo NA, Michelino MU, Brandalise NA, et al. Incidence and spidemiology of Barrett’s wpithelium at the Gastrocentro-UNICAMP[J]. Arq Gastroenterol, 1997, 34: 22-26.
[7] Maxdonald CE, Wicks AC, Playford RJ. Ten years expericence of screening patients with Barrett’s esophagus in a university teaching hospital[J]. Gut, 1997, 41: 303-307.
[8] Bozumslin EM, Herliny KJ. Barrett’s esophagus [J]. Ann Intem Med, 1992, 97: 103-107.
[9]侯晓华.胃食管反流病[A].王吉耀.内科学[M].第一版.北京:人民卫士出版社2005, 401.
[10] MengesM, MullerM, Zeitzm, lncreasedacideandbilertefuxin Barrett’s esophagus Compared To reflux esophagitis, and offect of protonPump inhibitortherapy [J]. AmJ Gastroenterol, 2001, 96(3): 331-337.
[11] Yehe, Hsu CT, Ho AS, et al. Esophagitis and Barrett’s esophagus in Tai Wan: a high frequency than expected [J]. Dis Sci, 1997, 42: 702-706.
[12]赵立群,徐峰,杨观瑞等. Barrett食管在国人中发病率及P53、EGF1在其中的表达[J].河南肿瘤学杂志, 1997,(10)3: 161-164.
[13]赵晶京,房殿春. Barrett食管放大内镜下分型与组织病理学关系的研究[J].中华消化内镜杂志, 2005, 22(3): 154-156.
[14] Cossentino MJ, Wong RK. Barrett′s esophagus and risk of esophageal adenocarcinoma [J]. Sem in Gastrointest Dis, 2003, 14: 128-135.
[15] Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and norman Barrett. Gastroenterology, 1996, 110(2): 614-621.
[16] Ortiz Hidalgo C, De La Vega G, Aguirre Garcia J. The histopathology and biologic Prognostic factors of Barrett’s esophagus: a review. J Clin Gastroenterol, 1998, 26(4): 324-333.
[17] Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized Controlled trial. JAMA, 2001, 285(18): 2331-2338.
[18] Schnell TG, Sontag SJ, Chejfec G. Adenocarcinoma arising in tongues or short segment of Barrett’s esophagus. Dig Dis Sci, 1992, 37(1): 137-143.
[19] Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in short-segment Barrett’s esophagus: a prospective 3-year follow-up. Am J Gastroenterol, 1997, 92(11): 2012-2016.
[20] Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett′s esophagus [J]. Gastroenterology, 1995, 109:1541-1546.
[21] Ormsby AH,Goldblum JR, Rice RW, et al. Cytokeratin subser can reliably siatinguish Barrett’s esophagus from gastrointestinal metaplasia in endoscopic biopsy specimens [J]. Gastroenterology, 1999, 116: H1196.
[22] Vaezi MF, Ormsby AH, Gramllich TL, et al. Cytoleratin stain to distinuish short-segment Barrett’s Esophagus from intestinal metaplasia of the Esophag ogastricjunction [J]. Gastroenterology, 1999, 116: G1489.
[23]张丽华,黄勤,于成功. Barrett食管及相关疾病的诊断和注意的问题.现代消化及介入诊疗, 2006;11(1):26-28
[24] Inoue H, Rey JF, Lightdale C. Lugol chromomendoscopy for esophageal squamous cell cancer. Endoscopy, 2001, 33(Ⅰ): 75-79.
[25] Fennerty MB. Tissue staining(chromoscopy)of the gastrointestinal tract. Can J Gastroent, 1999, 13(5):423-429.
[26] Canto MI. Staning in gastrointestinal endoscopy: the basics[J]. Endoscopy, 1999, 31(6): 479-486.
[27]罗和生.色素内镜的临床应用[J].医师进修杂志, 2001, 24(7):12-13.
[28]李军,高友芝,王元平,等.开展色素内镜提高早期食管与胃癌的检出率[J].中国腹部疾病杂志, 2001, 1(6):551-552.
[29] Eggerk, Werner M, Meining A, et al. Biopsy sureillance is still necessary in patients with Barrett’s oesophagus despite new endoscopic imaging techniques. Gut, 2003, 52: 18-23.
[30] Kouklakis GS, Kounttouras J, Dokas S M, et al. Methylene blue chronmo endoscopy for the detection of Barrett’s esophagus in a Greek cohort [J]. Endoscopy, 2003, 35(5): 383-387.
[31] Duncan M B, Horwhat J D, Maydonovitch C L, et al. Use of Methylenen Blue for Detection of Specialized Intestinal Metaplasia in GERD Patients Presenting for Screening Upper Endoscopy [J]. Dig Dis Sci, 2005, 50(2): 389-393.
[32]朱炳良,李佳,陈静.亚甲蓝染色对Barrett食管伴肠化诊断的临床价值,中国消化内镜杂志, 2007, 24(5):376-377.
[33] Olliver JR,Wild CP, Sahay P, et al. Chromoendoscopy with methylene blue and associated DNA damage in Barrett’s oesophagus. Lancet, 2003, 362: 373-374.
[34] Yokoo H. Barrett’s esophagus. Gastroenterology, 1996, 111(2): 565-566.
[35]李拥宁,李迎彤,覃英姿,等.色素内镜对上消化道早期癌及癌前病变的诊断价值(附98例病例分析).现代消化及介入诊疗, 2006, 11(2):103-105.
[36] Shmizuy, Tukagoshih, Dujitam, et al. Endoscopic screening for early esophageal cancer by iodine staining in patients with other current or prior primary cancer [J]. Gastrointest Endoec, 2001, 53(1):1.
[37]胡鹏飞,钟广芝,张庆等.内镜下碘染色对Barrett食管的诊断价值.临床消化病学杂志, 2008, 20(5):772-773.
[38] Villanacci V, Rossi E, Zambelli C, et al. COX-2, CDX2, and CDC2 immuno Histochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus. Dig Liver Dis, 2007, 39: 305.
[39]邹勍,黄石. Barrett食管和食管腺癌组织中Bcl-2和p53蛋白表达及其相关性研究.内科急危重症杂志, 2006, 12:128.
[40] Wongsurawat VJ, Finley JC, Galipeau PC, et al. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation. Cancer Epidemiol Biomarkers Prev, 2006, 15: 509.
[41] Lao-Sirieix P, RoyA, WorrallC, et al. Effect of acid suppression on molecular dictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev, 2006, 15(2): 288-293.
[42] Oyama K, Fujimura T, Ninomiya IA, et al. A COX-2 inhibitor prevents the esophageal Inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis, 2005, 26 (3): 565-570.
[43] Corfield A P, Carroll D, Myerscough N, et al. Mucins in the gast rointestinal t ract in health and disease [J]. Front Bio sci, 2001, 6: 1321-1357.
[44] Gum J R J r, Crawley S C, Hicks J W, et al. MUC17, a novel Membrane-tet hered mucin [J]. Biochem Biophys Res Commun, 2002, 291(3): 466-475.
[45] Chen Y, Zhao YH, Kalaslavadi TB, et al. Genome2wide search and identification of anovel gel-forming mucin MUC19/Muc19 in glandular tissues [J]. Respir cell Mol Biol, 2004, 30(2):155-165.
[46] Hiquchi T, Orita T, Nakanishi S, et al. Molecular cloning,genomic st ruct ure, and expression analysis of MUC20, a novel mucin protein, up-regulated in inured kidney[J]. J Biol Chem, 2004, 279(3): 1968-1979.
[47] O’Brien T, Beard B, Underwood L, et al. The CA 125 gene: an extracellular superst ruct ure do minated by repeat sequences [J]. Tumor Biol 2001, 22(6): 348-366.
[48] Yin BW, Lloyd KO. Molecular cloning of t he CA125 ovarian cancer antigen: identification as a new mucin, MUC16 [J]. J Biol Chem, 2001, 276(29): 27371-27375.
[49]肖春卫,易永芳. MUC1、MUC2及MUC5在大肠粘液腺癌组织中的表达及意义.实用癌症杂志, 2007, 22(1):47-49.
[50] Eda A, Osawa H, Satoh K, et al. Aberrant expression of CDX2 in Barrett’s epithelium and inflammatory esophageal mucosa. J Gastroenterol. 2003, 38: 14-22.
[51] Yamamoto H, Bai YQ. Yuasa Y. Homeodomain protein CDX2 regulate gobel-specific MUC2 gene expression. Biochem Biophys Res Conmun, 2003, 300: 813-818.
[52]李妹,王邦茂,张洁等. Cdx2和MUC2在反流性食管炎、Barrett食管和食管腺癌中的表达.中国消化内镜杂志, 2006, 23(5):355-357.
[53]刘杲,童仕伦. CDX2和MUC2在胃癌组织中的表达及意义.武汉大学学报, 2007, 28(3):365-368.
[54] Gulmaun C, Shaqaqi OA, Grace A, et al. Cytokeratin 7/20 and MUC1, 2,5AC, and 6 expression Patterns in Barrett’s esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related toBarrett’s esophagus. Appl immuno- histochem Mol Morphol, 2004, 12: 142-147.
[55] Glickman JN, Shahsafaei A, Odze RD. Mucin core peptide expression can help differentiate Barrett’s esophagus from intestinal metaplasia of the stomach. Am J Surg Pathol, 2003, 27: 1357-1365.
[56]赵晶京,房殿春,汪荣泉等. Barrett食管粘蛋白表达及意义.中华消化内镜杂志, 2007, 24(6).
[57]李昕,曹晓沧.消化内镜检查中使用染色剂的安全性问题.中华消化内镜杂志, 2007, 24(5):399-400.
[1]钟良,孙大裕.内镜在消化系统疾病中的应用.陈灏珠主编.实用内科学.北京:人民卫生出版社, 2005, 1810.
[2] Inoue H, Rey JF, Lightdale C. Lugol chromomendoscopy for esophageal squamous cell cancer. Endoscopy, 2001, 33 (1): 75-79.
[3] Fennerty MB. Tissue staining(chromoscopy)of the gastrointestinaltract. Can J Gastroent, 1999, 13(5):423-429.
[4] Canto MI. Staning in gastrointestinal endoscopy: the basics [J]. Endos-copy, 1999, 31(6): 479-486.
[5]罗和生.色素内镜的临床应用[J].医师进修杂志, 2001, 24(7):12-13.
[6]李军,高友芝,王元平,等.开展色素内镜提高早期食管与胃癌的检出率[J].中国腹部疾病杂志, 2001, 1(6):551-552.
[7]李昕,曹晓沧.消化内镜检查中使用染色剂的安全性问题.中华消化内镜杂志, 2007, 24(5):399-400.
[8] Solid Waste and Emergency Response. Enviromental fact sheethazardous waste lis-Ting determination for teo dye and pigment waste. EPA, 1999, S30-F99-037.
[9]钟金汤.偶氮染料及其代谢产物的化学结构与毒性关系的回顾与前瞻.环境与职业医学, 2004, 21:58-62.
[10]吴海霞,康敬万,李志峰,等.亚甲蓝与DNA相互作用的电化学研究.分析测试学报, 2006, 25:1-5.
[11] Boiteux S, Gajewski E, Laval J, et al. Substrate specificity of the Escherchia coli FPG protein (formamidopyrimidine-DNA glycosylase): excision of purine lesions in DNA produced by ionizing radiation or photosensitisation. Biochemistry, 1992, 31: 106-110.
[12] Abbruzzetti S, Viappiani C, Murgida DH, et al. Non-toxic watersoluble photocalori- metric reference compounds for UV and visible excitation. Chem Phys Lett, 1999, 304:167-172.
[13] Olliver JR, Wild CP, Sahay P, et al. Chromoendscopy with methlene blue and asso-ciated DNA damage in Barrett’s esophagus. Lancet, 2003, 362: 373-374.
[14]刘复生,刘彤华.肿瘤病理学[M].北京:北京医科大学中国协和医科大学联合出版社, 1997. 4-5.
[15]李宏,付小梅,丛庆文,等.食管癌前病变及其诊断的研究进展.临床荟萃, 2004, 19(24):1421-1423.
[16] Barrett NR. Chronic peptic ulcer of the esophagus and“esophagitis”. Br J Surg, 1950, 38(2): 175-182.
[17] Hayward J. The lower end of the esophagus. Thorax 1961, 16(1):36-41.
[18]中华医学会消化病学会. Barrett食管诊治共识(2005重庆草案).胃肠病学和肝脏病学杂志, 2006, 15(1):80-81.
[19] Pera M. Came ron AJ, Trastek VF, et al. Increasing incidence of denocarcinoma of the esophagus and sophagogastricjunction. Gastroenterology, 1993, 104(2): 510-513
[20] Cossentino MJ, Wong RK. Barrett′s esophagus and risk of esophageal adeno-carcinoma [J]. Sem in Gastrointest Dis, 2003, 14: 128-135.
[21] Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett’s esophagus. in Oimsted Country, Minnesota. Gut, 2001, 48(3):304-309
[22]张丽华,黄勤,于成功. Barrett食管及相关疾病的诊断和注意的问题.现代消化及介入诊疗, 2006;11(1):26-28
[23] Boyee HW. Barrett esophagus: endoscopic findings and what to biopsy [J]. J Clin Gastroenterol, 2003, 36(SupplⅠ): 6-18
[24]穆华. Barrett食管研究新进展.内科急危重症杂志, 2007, 13(4):150-152.
[25] Sharma P, Marcon N, Wani S, et al. Nonbiopsy detectiong of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study. Endoscopy, 2006,38:1206.
[26] Dacosta R S, Wilson B C, Marcon N E. New optical technologies for earlier endoscopic diagnosisi of premalignant gastrointestinal lesions [J]. J Gastroenterol Hepatol, 2002, 17(Suppl): 85-104.
[27] Kouklakis G S, Kounttouras J, Dokas S M, et al. Methylene blue chronmo endoscopy for the detection of Barrett’s esophagus in a Greek cohort [J]. Endoscopy, 2003, 35(5): 383-387.
[28] Duncan M B, Horwhat J D, Maydonovitch C L, et al. Use of Methylenen Blue for Detection of Specialized Intestinal Metaplasia in GERD Patients Presenting for Screening Upper Endoscopy [J]. Dig Dis Sci, 2005, 50(2): 389-393.
[29] Egger K, Wernener M, Meining A, et al. Biopsy surveilance is still necessary in patients with Barrett’s esophagusdespite new endoscopic imaging techniques [J]. Gut, 2003, 52(Ⅰ): 18-23.
[30]朱炳良,李佳,陈静.亚甲蓝染色对Barrett食管伴肠化诊断的临床价值.中华消化内镜杂志, 2007, 24(5):376-377.
[31] Amano Y. Chromoendoscopic diagnsis of Barrett’s esophagus [J]. Nippon R insho, 2005, 63(8): 1416.
[32]胡鹏飞,钟广芝,张庆,等.内镜下碘染色对Barrett食管的诊断价值.临床消化病杂志, 2008, 20(5):772.
[33]邓登豪,朱海杭,罗金燕,等.内镜下Toluidine Blue和Lugol’s Solution双重染色在食管早期癌和浅表癌诊断中的意义[J].中国内镜杂志, 2001, 7(2):21-23.
[34]李拥宁,李迎彤,覃英姿,等.色素内镜对上消化道早期癌及癌前病变的诊断价值(附98例病例分析).现代消化及介入诊疗, 2006, 11(2):103-105.
[35]张军,龚均,罗金燕,等.卢戈氏染色诊断食管早期癌和表浅癌价值的评价[J].中华消化内镜杂志, 1998, 15(3): 142-144.
[36] Areia M, Amaro P, Dinis-Ribeiro M, et al. External validation of a classiifcation formethylene blue magniifcation chromoendoseopy in premalignant gastriclesions [J].Gastrointest Endosc, 2008, 67(7):1011-1018.
[37] Yamamoto H.Technology insight:endoscopic submucosal dissection of Gastrointestinal neoplasms[J]. Nat Clin Pract Gastroenterol Hepatol, 2007, 4(9):511-520.
[38]包怀鸣,陈志荣,陈卫昌,等.早期胃癌的内镜诊断和治疗进展.医学综述, 2006, 12:303.
[39]杨少波,王孟薇,张子其.胃癌前粘膜变化的自然演变规律研究.中国综合临床, 2005, 21(3):193-194.
[40]杜林枫,蒋军,杨志,等.色素内镜对胃粘膜肠上皮化生的分析及诊断价值.现代消化及介入诊疗, 2006, 11(1):59-60.
[41]张欣,王国祥,王建文,等.色素内镜对早期胃癌及癌前病变的诊断价值.胃肠病学和肝病学杂志, 2008, 17(10):820-823.
[42]焦洋,杨冬野,张建生,等.色素内镜在胃凹陷型病变性质判断中的作用.临床荟萃, 2005, 20(22):1291-1292.
[43] Chen L, Fang DC, Li XH, et al. The use of magnifying chromoendoscopyin early detection of gastirc cancer and its precancerous lesions [J]. Med J Chin PLA, 2005, 30(9):807-809.
[44]陈磊,房殿春,李向红,等.放大色素内镜诊断早期胃癌及其癌前病变[J].解放军医学杂志, 2005, 30(9):807-809.
[2]孙燕,哈献文.临床肿瘤诊疗关键[M]南宁;广西科学技术出版社, 1999;09:313.
[3] KE L. Mortality and incidence trends from esophagus cancer in selected geographic areas of China cirea 1970-90 [J]. Int J Cancer 2002, 102(3): 271-274.
[4] Zhiwei Dong, Pingzhang Tang, Liandi Li, et al. The Strategy for EsophagealCancer Control in High-risk Areas of China. Jpn. J. Clin. Oncol., Feb 2002; 32: S10-S12.
[5]李超民,刘佳萍,何洪,等.邵阳市食管癌207例临床及内镜分析[J].中国内镜杂志, 2004, 10(3): 70-71.
[6]李宁燕,何慧萍,汪雪琦,等. 367例食管癌胃镜诊断及病理分析[J].实用诊断与治疗杂志, 2004, 18(6): 554-554.
[7] G Launoy, J Faivre, P Pienkowski, et al. Changing Pattern of Oesophageal Cancer Incidence in France. Int. J.Epidemiol., Apr1994, 23: 246-251.
[8] Akiko Shibata, Toru Matsuda, Wakiko Ajiki, et al. Trend in Incidence of A denocarcinoma of the Esophagus in Japan, 1993–2001. Japanese Journalof Clinical Oncology, 2008, 38(7): 464-468.
[9]汤钊猷.现代肿瘤学[M].上海医科大学,1993;06:456-484.
[10]侯浚,陈志峰,贺宇彤.食道癌的流行病学.河北职工医学院学报[J]. 2000, 127(4):28-30.
[11]郭国平,华召来,周琴等.扬州市食道癌流行及治疗情况分析[J].中国肿瘤, 2001, 10(2):105-107.
[12]罗好曾,周俊年,刘文林.武威市食道癌发病对比分析.肿瘤防治学杂志[J].2002, 9(2):121-123.
[13]朱健,姚红玉,张永辉.启东市1972～2000年食道癌发病趋势分析.交通医学[J]. 2002, 16(4):426-427.
[14] Gary D. Stoner, Ashok Gupta. Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis, 2001, 22 (11): 1737-1746.
[15]魏矿荣,沈逸雄,梁治恒,等.广东省中山市1970～1999年食道癌发病动态分析.实用肿瘤学杂志[J]. 2003, 17(4):246-249.
[16]余红平,施侣元,幺鸿雁.吸烟、饮酒与食管癌关系的Meta-分析.中国慢性病预防与控制[J]. 2003, 11(1): 1-2.
[17]肖郑生,张立新,杨海军,等.食管癌3954例切除标本临床病理分析.中国肿瘤临床与康复[J]. 2002, 9(1): 59-61.
[18]章宏,厉有名,王伟.食道腺癌临床流行病学研究.中华消化杂志, 2003, 23:696-697.
[19] Douglas A Corley, Patricia A Buffler. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. International Journal of Epidemiology, 2001, 30: 1415-1425.
[20] Ritenbaugh C, Sampliner R, Aickin M, et al. Risk factor for Barrett’s oesophagus: a life history approach to bahavioural assessment in the distant past. Eur J Cancer Prev, 1995, 4(6): 459-468.
[21]林三仁,许国铭,胡品津等.中国胃食管反流病共识意见.胃肠病学, 2007, 12(4):233-239.
[22] Devesa SS, Blot WJ, Fraumeni JF, et al. Changing patterns in the irrcidence of esophageal and gastric carcinoma in the United States. Cancer, 1998, 83(10): 2049-2053.
[23] Xiaoxin Chen , Chung S. Yang. Esophageal adenocarcinoma: a review and perspectiveson the mechanism of carcinogenesis and chemoprevention.Carcinogenesis, 22(8): 1119 -1129.
[24] Ofman JJ. The relation between gastroesophageal reflux disease and esophageal and head and neck cancer; a critical appraisal of epidemiologic literature. Am J Med, 2001, 111(Suppl 8A): 124S-129S.
[25]刘巍,郝希山,晋颖,等. 4329例手术后食管癌临床病理资料分析.中国肿瘤临床[J]. 2008, 35(5): 241-244.
[26]马兴刚,黄根牙,张菊,等.淮安市666例食管癌的临床、内镜及病理分析.医学综述, 2008, 14(17):2705.
[27]厉有名.重视食管腺癌的基础和临床研究.中华消化杂志, 2002, 22:261-262.
[28] Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalenceand clinical data. Gastroenterology, 1999, 116: 277-285.
[29]汤绍辉,杨冬华. Barrett食管.杨冬华.消化系统疾病治疗学[M].第1版.北京:人民卫生出版社, 2005, 60.
[30] Kulke MH, Odze RD, Thakore KS, et al. Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett’s oesophagus associated adenocar cinima[J]. Br J Cancer, 2001, 84(6): 748-753.
[31] Menges M, Muller M, Zeitzm, Increased acide and bilentefux in Barrett’s esophagus compared to reflux esophagitis,and effect of proton pump inhibitor therapy [J]. Am J Gastroenterol, 2001, 96(3): 331-337.
[32]侯晓华.胃食管反流病.王吉耀.内科学[M].第一版.北京:人民卫士出版社, 2005, 401.
[33] Yehe, Hsu CT, Ho AS, et al. Esophagitis and Barrett’s esophagus in Tai Wan: a high frequency than expected [J]. Dis Sci, 1997, 42: 702-706.
[34]赵京晶,房殿春. Barrett食管放大内镜下分型与组织病理学关系的研究.中华消化内镜杂志[J]. 2005, 22(3):154-156.
[35]赵立群,徐峰,杨观瑞,等. Barrett食管在国人中发病率及P53、EGF1在其中的表达河南肿瘤学杂志[J]. 1997,(10)3:161-164.
[1] Burjonrappa SC, Reddimasu S, Nawaz Z, et al. Mucin expression profile in Barrett’s, dysplasia, adenocarioma sequence in the esophagus. Indian J Cancer, 2007, 44: 1.
[2]林三仁,许国铭,胡品津等.中国胃食管反流病共识意见.胃肠病学, 2007, 12(4):233-239.
[3]薛寒冰译. Barrett食管诊断和治疗-美国胃肠病学会芝加哥会议总结.胃肠病学, 2005, 10(3):182.
[4]小森真人. Barrett上皮的发生机制.日本医学介绍, 2002, 23(1):5.
[5] Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett’s esophagus. in Oimsted Country, Minnesota. Gut, 2001, 48(3):304-309
[6] Andreollo NA, Michelino MU, Brandalise NA, et al. Incidence and spidemiology of Barrett’s wpithelium at the Gastrocentro-UNICAMP[J]. Arq Gastroenterol, 1997, 34: 22-26.
[7] Maxdonald CE, Wicks AC, Playford RJ. Ten years expericence of screening patients with Barrett’s esophagus in a university teaching hospital[J]. Gut, 1997, 41: 303-307.
[8] Bozumslin EM, Herliny KJ. Barrett’s esophagus [J]. Ann Intem Med, 1992, 97: 103-107.
[9]侯晓华.胃食管反流病[A].王吉耀.内科学[M].第一版.北京:人民卫士出版社2005, 401.
[10] MengesM, MullerM, Zeitzm, lncreasedacideandbilertefuxin Barrett’s esophagus Compared To reflux esophagitis, and offect of protonPump inhibitortherapy [J]. AmJ Gastroenterol, 2001, 96(3): 331-337.
[11] Yehe, Hsu CT, Ho AS, et al. Esophagitis and Barrett’s esophagus in Tai Wan: a high frequency than expected [J]. Dis Sci, 1997, 42: 702-706.
[12]赵立群,徐峰,杨观瑞等. Barrett食管在国人中发病率及P53、EGF1在其中的表达[J].河南肿瘤学杂志, 1997,(10)3: 161-164.
[13]赵晶京,房殿春. Barrett食管放大内镜下分型与组织病理学关系的研究[J].中华消化内镜杂志, 2005, 22(3): 154-156.
[14] Cossentino MJ, Wong RK. Barrett′s esophagus and risk of esophageal adenocarcinoma [J]. Sem in Gastrointest Dis, 2003, 14: 128-135.
[15] Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and norman Barrett. Gastroenterology, 1996, 110(2): 614-621.
[16] Ortiz Hidalgo C, De La Vega G, Aguirre Garcia J. The histopathology and biologic Prognostic factors of Barrett’s esophagus: a review. J Clin Gastroenterol, 1998, 26(4): 324-333.
[17] Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized Controlled trial. JAMA, 2001, 285(18): 2331-2338.
[18] Schnell TG, Sontag SJ, Chejfec G. Adenocarcinoma arising in tongues or short segment of Barrett’s esophagus. Dig Dis Sci, 1992, 37(1): 137-143.
[19] Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in short-segment Barrett’s esophagus: a prospective 3-year follow-up. Am J Gastroenterol, 1997, 92(11): 2012-2016.
[20] Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett′s esophagus [J]. Gastroenterology, 1995, 109:1541-1546.
[21] Ormsby AH,Goldblum JR, Rice RW, et al. Cytokeratin subser can reliably siatinguish Barrett’s esophagus from gastrointestinal metaplasia in endoscopic biopsy specimens [J]. Gastroenterology, 1999, 116: H1196.
[22] Vaezi MF, Ormsby AH, Gramllich TL, et al. Cytoleratin stain to distinuish short-segment Barrett’s Esophagus from intestinal metaplasia of the Esophag ogastricjunction [J]. Gastroenterology, 1999, 116: G1489.
[23]张丽华,黄勤,于成功. Barrett食管及相关疾病的诊断和注意的问题.现代消化及介入诊疗, 2006;11(1):26-28
[24] Inoue H, Rey JF, Lightdale C. Lugol chromomendoscopy for esophageal squamous cell cancer. Endoscopy, 2001, 33(Ⅰ): 75-79.
[25] Fennerty MB. Tissue staining(chromoscopy)of the gastrointestinal tract. Can J Gastroent, 1999, 13(5):423-429.
[26] Canto MI. Staning in gastrointestinal endoscopy: the basics[J]. Endoscopy, 1999, 31(6): 479-486.
[27]罗和生.色素内镜的临床应用[J].医师进修杂志, 2001, 24(7):12-13.
[28]李军,高友芝,王元平,等.开展色素内镜提高早期食管与胃癌的检出率[J].中国腹部疾病杂志, 2001, 1(6):551-552.
[29] Eggerk, Werner M, Meining A, et al. Biopsy sureillance is still necessary in patients with Barrett’s oesophagus despite new endoscopic imaging techniques. Gut, 2003, 52: 18-23.
[30] Kouklakis GS, Kounttouras J, Dokas S M, et al. Methylene blue chronmo endoscopy for the detection of Barrett’s esophagus in a Greek cohort [J]. Endoscopy, 2003, 35(5): 383-387.
[31] Duncan M B, Horwhat J D, Maydonovitch C L, et al. Use of Methylenen Blue for Detection of Specialized Intestinal Metaplasia in GERD Patients Presenting for Screening Upper Endoscopy [J]. Dig Dis Sci, 2005, 50(2): 389-393.
[32]朱炳良,李佳,陈静.亚甲蓝染色对Barrett食管伴肠化诊断的临床价值,中国消化内镜杂志, 2007, 24(5):376-377.
[33] Olliver JR,Wild CP, Sahay P, et al. Chromoendoscopy with methylene blue and associated DNA damage in Barrett’s oesophagus. Lancet, 2003, 362: 373-374.
[34] Yokoo H. Barrett’s esophagus. Gastroenterology, 1996, 111(2): 565-566.
[35]李拥宁,李迎彤,覃英姿,等.色素内镜对上消化道早期癌及癌前病变的诊断价值(附98例病例分析).现代消化及介入诊疗, 2006, 11(2):103-105.
[36] Shmizuy, Tukagoshih, Dujitam, et al. Endoscopic screening for early esophageal cancer by iodine staining in patients with other current or prior primary cancer [J]. Gastrointest Endoec, 2001, 53(1):1.
[37]胡鹏飞,钟广芝,张庆等.内镜下碘染色对Barrett食管的诊断价值.临床消化病学杂志, 2008, 20(5):772-773.
[38] Villanacci V, Rossi E, Zambelli C, et al. COX-2, CDX2, and CDC2 immuno Histochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus. Dig Liver Dis, 2007, 39: 305.
[39]邹勍,黄石. Barrett食管和食管腺癌组织中Bcl-2和p53蛋白表达及其相关性研究.内科急危重症杂志, 2006, 12:128.
[40] Wongsurawat VJ, Finley JC, Galipeau PC, et al. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation. Cancer Epidemiol Biomarkers Prev, 2006, 15: 509.
[41] Lao-Sirieix P, RoyA, WorrallC, et al. Effect of acid suppression on molecular dictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev, 2006, 15(2): 288-293.
[42] Oyama K, Fujimura T, Ninomiya IA, et al. A COX-2 inhibitor prevents the esophageal Inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis, 2005, 26 (3): 565-570.
[43] Corfield A P, Carroll D, Myerscough N, et al. Mucins in the gast rointestinal t ract in health and disease [J]. Front Bio sci, 2001, 6: 1321-1357.
[44] Gum J R J r, Crawley S C, Hicks J W, et al. MUC17, a novel Membrane-tet hered mucin [J]. Biochem Biophys Res Commun, 2002, 291(3): 466-475.
[45] Chen Y, Zhao YH, Kalaslavadi TB, et al. Genome2wide search and identification of anovel gel-forming mucin MUC19/Muc19 in glandular tissues [J]. Respir cell Mol Biol, 2004, 30(2):155-165.
[46] Hiquchi T, Orita T, Nakanishi S, et al. Molecular cloning,genomic st ruct ure, and expression analysis of MUC20, a novel mucin protein, up-regulated in inured kidney[J]. J Biol Chem, 2004, 279(3): 1968-1979.
[47] O’Brien T, Beard B, Underwood L, et al. The CA 125 gene: an extracellular superst ruct ure do minated by repeat sequences [J]. Tumor Biol 2001, 22(6): 348-366.
[48] Yin BW, Lloyd KO. Molecular cloning of t he CA125 ovarian cancer antigen: identification as a new mucin, MUC16 [J]. J Biol Chem, 2001, 276(29): 27371-27375.
[49]肖春卫,易永芳. MUC1、MUC2及MUC5在大肠粘液腺癌组织中的表达及意义.实用癌症杂志, 2007, 22(1):47-49.
[50] Eda A, Osawa H, Satoh K, et al. Aberrant expression of CDX2 in Barrett’s epithelium and inflammatory esophageal mucosa. J Gastroenterol. 2003, 38: 14-22.
[51] Yamamoto H, Bai YQ. Yuasa Y. Homeodomain protein CDX2 regulate gobel-specific MUC2 gene expression. Biochem Biophys Res Conmun, 2003, 300: 813-818.
[52]李妹,王邦茂,张洁等. Cdx2和MUC2在反流性食管炎、Barrett食管和食管腺癌中的表达.中国消化内镜杂志, 2006, 23(5):355-357.
[53]刘杲,童仕伦. CDX2和MUC2在胃癌组织中的表达及意义.武汉大学学报, 2007, 28(3):365-368.
[54] Gulmaun C, Shaqaqi OA, Grace A, et al. Cytokeratin 7/20 and MUC1, 2,5AC, and 6 expression Patterns in Barrett’s esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related toBarrett’s esophagus. Appl immuno- histochem Mol Morphol, 2004, 12: 142-147.
[55] Glickman JN, Shahsafaei A, Odze RD. Mucin core peptide expression can help differentiate Barrett’s esophagus from intestinal metaplasia of the stomach. Am J Surg Pathol, 2003, 27: 1357-1365.
[56]赵晶京,房殿春,汪荣泉等. Barrett食管粘蛋白表达及意义.中华消化内镜杂志, 2007, 24(6).
[57]李昕,曹晓沧.消化内镜检查中使用染色剂的安全性问题.中华消化内镜杂志, 2007, 24(5):399-400.
[1]钟良,孙大裕.内镜在消化系统疾病中的应用.陈灏珠主编.实用内科学.北京:人民卫生出版社, 2005, 1810.
[2] Inoue H, Rey JF, Lightdale C. Lugol chromomendoscopy for esophageal squamous cell cancer. Endoscopy, 2001, 33 (1): 75-79.
[3] Fennerty MB. Tissue staining(chromoscopy)of the gastrointestinaltract. Can J Gastroent, 1999, 13(5):423-429.
[4] Canto MI. Staning in gastrointestinal endoscopy: the basics [J]. Endos-copy, 1999, 31(6): 479-486.
[5]罗和生.色素内镜的临床应用[J].医师进修杂志, 2001, 24(7):12-13.
[6]李军,高友芝,王元平,等.开展色素内镜提高早期食管与胃癌的检出率[J].中国腹部疾病杂志, 2001, 1(6):551-552.
[7]李昕,曹晓沧.消化内镜检查中使用染色剂的安全性问题.中华消化内镜杂志, 2007, 24(5):399-400.
[8] Solid Waste and Emergency Response. Enviromental fact sheethazardous waste lis-Ting determination for teo dye and pigment waste. EPA, 1999, S30-F99-037.
[9]钟金汤.偶氮染料及其代谢产物的化学结构与毒性关系的回顾与前瞻.环境与职业医学, 2004, 21:58-62.
[10]吴海霞,康敬万,李志峰,等.亚甲蓝与DNA相互作用的电化学研究.分析测试学报, 2006, 25:1-5.
[11] Boiteux S, Gajewski E, Laval J, et al. Substrate specificity of the Escherchia coli FPG protein (formamidopyrimidine-DNA glycosylase): excision of purine lesions in DNA produced by ionizing radiation or photosensitisation. Biochemistry, 1992, 31: 106-110.
[12] Abbruzzetti S, Viappiani C, Murgida DH, et al. Non-toxic watersoluble photocalori- metric reference compounds for UV and visible excitation. Chem Phys Lett, 1999, 304:167-172.
[13] Olliver JR, Wild CP, Sahay P, et al. Chromoendscopy with methlene blue and asso-ciated DNA damage in Barrett’s esophagus. Lancet, 2003, 362: 373-374.
[14]刘复生,刘彤华.肿瘤病理学[M].北京:北京医科大学中国协和医科大学联合出版社, 1997. 4-5.
[15]李宏,付小梅,丛庆文,等.食管癌前病变及其诊断的研究进展.临床荟萃, 2004, 19(24):1421-1423.
[16] Barrett NR. Chronic peptic ulcer of the esophagus and“esophagitis”. Br J Surg, 1950, 38(2): 175-182.
[17] Hayward J. The lower end of the esophagus. Thorax 1961, 16(1):36-41.
[18]中华医学会消化病学会. Barrett食管诊治共识(2005重庆草案).胃肠病学和肝脏病学杂志, 2006, 15(1):80-81.
[19] Pera M. Came ron AJ, Trastek VF, et al. Increasing incidence of denocarcinoma of the esophagus and sophagogastricjunction. Gastroenterology, 1993, 104(2): 510-513
[20] Cossentino MJ, Wong RK. Barrett′s esophagus and risk of esophageal adeno-carcinoma [J]. Sem in Gastrointest Dis, 2003, 14: 128-135.
[21] Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett’s esophagus. in Oimsted Country, Minnesota. Gut, 2001, 48(3):304-309
[22]张丽华,黄勤,于成功. Barrett食管及相关疾病的诊断和注意的问题.现代消化及介入诊疗, 2006;11(1):26-28
[23] Boyee HW. Barrett esophagus: endoscopic findings and what to biopsy [J]. J Clin Gastroenterol, 2003, 36(SupplⅠ): 6-18
[24]穆华. Barrett食管研究新进展.内科急危重症杂志, 2007, 13(4):150-152.
[25] Sharma P, Marcon N, Wani S, et al. Nonbiopsy detectiong of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study. Endoscopy, 2006,38:1206.
[26] Dacosta R S, Wilson B C, Marcon N E. New optical technologies for earlier endoscopic diagnosisi of premalignant gastrointestinal lesions [J]. J Gastroenterol Hepatol, 2002, 17(Suppl): 85-104.
[27] Kouklakis G S, Kounttouras J, Dokas S M, et al. Methylene blue chronmo endoscopy for the detection of Barrett’s esophagus in a Greek cohort [J]. Endoscopy, 2003, 35(5): 383-387.
[28] Duncan M B, Horwhat J D, Maydonovitch C L, et al. Use of Methylenen Blue for Detection of Specialized Intestinal Metaplasia in GERD Patients Presenting for Screening Upper Endoscopy [J]. Dig Dis Sci, 2005, 50(2): 389-393.
[29] Egger K, Wernener M, Meining A, et al. Biopsy surveilance is still necessary in patients with Barrett’s esophagusdespite new endoscopic imaging techniques [J]. Gut, 2003, 52(Ⅰ): 18-23.
[30]朱炳良,李佳,陈静.亚甲蓝染色对Barrett食管伴肠化诊断的临床价值.中华消化内镜杂志, 2007, 24(5):376-377.
[31] Amano Y. Chromoendoscopic diagnsis of Barrett’s esophagus [J]. Nippon R insho, 2005, 63(8): 1416.
[32]胡鹏飞,钟广芝,张庆,等.内镜下碘染色对Barrett食管的诊断价值.临床消化病杂志, 2008, 20(5):772.
[33]邓登豪,朱海杭,罗金燕,等.内镜下Toluidine Blue和Lugol’s Solution双重染色在食管早期癌和浅表癌诊断中的意义[J].中国内镜杂志, 2001, 7(2):21-23.
[34]李拥宁,李迎彤,覃英姿,等.色素内镜对上消化道早期癌及癌前病变的诊断价值(附98例病例分析).现代消化及介入诊疗, 2006, 11(2):103-105.
[35]张军,龚均,罗金燕,等.卢戈氏染色诊断食管早期癌和表浅癌价值的评价[J].中华消化内镜杂志, 1998, 15(3): 142-144.
[36] Areia M, Amaro P, Dinis-Ribeiro M, et al. External validation of a classiifcation formethylene blue magniifcation chromoendoseopy in premalignant gastriclesions [J].Gastrointest Endosc, 2008, 67(7):1011-1018.
[37] Yamamoto H.Technology insight:endoscopic submucosal dissection of Gastrointestinal neoplasms[J]. Nat Clin Pract Gastroenterol Hepatol, 2007, 4(9):511-520.
[38]包怀鸣,陈志荣,陈卫昌,等.早期胃癌的内镜诊断和治疗进展.医学综述, 2006, 12:303.
[39]杨少波,王孟薇,张子其.胃癌前粘膜变化的自然演变规律研究.中国综合临床, 2005, 21(3):193-194.
[40]杜林枫,蒋军,杨志,等.色素内镜对胃粘膜肠上皮化生的分析及诊断价值.现代消化及介入诊疗, 2006, 11(1):59-60.
[41]张欣,王国祥,王建文,等.色素内镜对早期胃癌及癌前病变的诊断价值.胃肠病学和肝病学杂志, 2008, 17(10):820-823.
[42]焦洋,杨冬野,张建生,等.色素内镜在胃凹陷型病变性质判断中的作用.临床荟萃, 2005, 20(22):1291-1292.
[43] Chen L, Fang DC, Li XH, et al. The use of magnifying chromoendoscopyin early detection of gastirc cancer and its precancerous lesions [J]. Med J Chin PLA, 2005, 30(9):807-809.
[44]陈磊,房殿春,李向红,等.放大色素内镜诊断早期胃癌及其癌前病变[J].解放军医学杂志, 2005, 30(9):807-809.